XTNTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Xtant Medical Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.29+0.00 (+1.50%)
Close on Oct 19, 2026
- Market cap
- $40.82M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
62.9%−1.6 pts over 5 years
Operating margin
5.4%+6.8 pts over 5 years
Net margin
3.7%+16.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +14.2% | +32.2% | +20.2% | +8.5% | |
| Gross profit | +23.5% | +37.9% | +19.6% | +8.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -2162.9% | 47.3% | 10.6% | |
| Return on assets | -13.7% | -16.6% | 5.3% | |
| Current ratio | 1.57 | 1.22 | 2.65 | |
| Debt to equity | – | – | 0.29 | |
| Net debt to EBITDA | – | – | -0.20× | |
| Interest coverage | -0.6× | -0.1× | 2.0× | |
| Inventory turnover | 1.1× | 1.0× | 1.4× | |
| Capex to revenue | 6.5% | 2.9% | 1.8% | |
| Diluted shares | 1M | 28M | 150M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Xtant Medical generated $39.74M from operations and spent $11.83M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$39.74M
Used
$11.83M
Capital expenditure$11.83M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3.7%
×Asset turnover1.42×
×Equity multiplier2.00×
=Return on equity, FY202510.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 3.7% | 1.42× | 2.00× | 10.6% |
| FY2024 | -14.0% | 1.26× | 1.98× | -34.9% |
| FY2023 | 0.7% | 1.19× | 1.79× | 1.5% |
| FY2022 | -14.6% | 1.01× | 1.77× | -26.1% |
| FY2021 | -8.8% | 1.15× | 2.12× | -21.4% |
| FY2020 | -13.2% | 1.26× | -2.85× | 47.3% |
| FY2019 | -12.7% | 1.44× | -1.02× | 18.7% |
| FY2018 | -97.1% | 0.95× | -1.48× | 136.8% |
| FY2017 | -63.4% | 0.66× | -3.80× | 159.4% |
| FY2016 | -21.7% | 0.63× | 158.18× | -2162.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$4.97M
- Cash generatingOperating cash flow above zero$12.55M
- Return on assets improvedROA up on the prior year-17.8% → 5.3%
- Earnings backed by cashOperating cash flow above net income$12.55M vs $4.97M
- Less leverageLong-term debt to assets fell23.5% → 11.7%
- Better liquidityCurrent ratio rose2.35 → 2.65
- No dilutionShare count did not rise134M → 150M
- Gross margin improvedGross margin up on the prior year58.17% → 62.92%
- More efficientAsset turnover rose1.27 → 1.43